Search

Displaying results 1101 - 1110 of 10000 in total
  1. Drug

    Zunsemetinib

    go.drugbank.com/drugs/DB16502
    Investigational

    Additionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis. … Zunsemetinib is being investigated in a new clinical trial (NCT06374459) for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with bone metastasis.

    Synonyms: (2′S)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2′-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5′,6-dimethyl[1(2H),4′-bipyridin]-2-one, (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one
  2. Drug

    BCc1

    go.drugbank.com/drugs/DB16504
    Experimental

    BCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.

  3. Drug

    beta-Hydroxybutyric acid

    go.drugbank.com/drugs/DB16506
    Investigational

    diabetes), and NCT05581043 (completed for type 2 diabetes). … studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236 (completed for type 1

    Synonyms: 3-HYDROXYBUTYRIC ACID, 3-HYDROXY-BUTANOIC ACID
  4. Drug

    AT-301

    go.drugbank.com/drugs/DB16507
    Investigational

    AT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine

  5. Drug

    HLX70

    go.drugbank.com/drugs/DB16509
    Investigational

    HLX70, a recombinant humanized anti-S protein monoclonal antibody intended for intravenous infusion, was under investigation in clinical trials NCT05429385 and NCT04561076 to evaluate its safety and pharmacokinetics

  6. Drug

    MPT0B640

    go.drugbank.com/drugs/DB16512
    Investigational

    MPT0B640 was under investigation in clinical trials NCT04526717 for COVID-19 infection and NCT04294875 for locally advanced or metastatic solid malignancies.

  7. Drug

    TM5614

    go.drugbank.com/drugs/DB16516
    Investigational

    TM5614 is a novel, orally active, plasminogen activator inhibitor 1 (PAI-1) inhibitor[A228788,A228793,]. … PAI-1 is a marker of obesity, type 2 diabetes, and metabolic syndrome[L31673,A228793,A228798], and current studies are exploring downstream effects of its inhibition.

  8. Drug

    Prolectin-M

    go.drugbank.com/drugs/DB16521
    Investigational

    Prolectin-M is a (1-6)-alpha-D-mannopyranose[L31338] and acts as an antagonist of galectin. … [L31343] It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)).

    Synonyms: Prolectin-M
  9. Drug

    Sodium copper chlorophyllin

    go.drugbank.com/drugs/DB16522
    Investigational

    SCC of the commercial-grade is prepared from a reaction between a crude chlorophyll extract and methanolic sodium hydroxide, followed by replacement of the central magnesium atom with a heavy metal[A227718 … This compound is used as a food colorant and supplement[A227718].

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds with 4 or More Rings
  10. Drug

    FINLAY-FR-1

    go.drugbank.com/drugs/DB16524
    Experimental

    , of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule. … FINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute[L31373].

    Synonyms: FINLAY-FR-1 anti-SARS-CoV-2 vaccine candidate